Anygen Co., Ltd. Patent applications |
Patent application number | Title | Published |
20140256623 | TRANSMUCOSAL DELIVERY OF PHARMACEUTICAL ACTIVE SUBSTANCES - Provided is a conjugate including a pharmacologically active substance covalently bound to chitosan or its derivative and a method for transmucosal delivery of a pharmacologically active substance using the same. Specifically a conjugate includes a pharmacologically active substance covalently bound via a linker to chitosan; and a pharmaceutical composition for transmucosal administration of a drug includes the aforementioned conjugate and a pharmaceutically acceptable carrier. Further provided is a method for in vivo delivery of a pharmacologically active substance via a transmucosal route, by covalent binding of the active substance with chitosan or its derivative via a linker. The conjugate in accordance with the present invention exhibits excellent absorption rate and biocompatibility in biological mucous membranes, particularly mucous membranes of the alimentary canal (especially the gastrointestinal tract), in vivo degradability, and superior bioavailability even with oral administration, thus enabling treatment of diseases via oral administration of a drug. | 09-11-2014 |
20130345141 | COMPOSITION FOR REGULATING CIRCADIAN RHYTHMS, COMPOSITION FOR DIAGNOSING CIRCADIAN RHYTHM DISORDERS AND DIAGNOSTIC KIT - The present invention relates to a composition for regulating circadian rhythms, a composition for diagnosing circadian rhythm disorders and a diagnostic kit, wherein the composition for regulating circadian rhythms comprises NQ peptides, C12orf39 genes, NQ peptides cDNA and the like, which relate to circadian regulation in vertebrates as main components. | 12-26-2013 |
20120295948 | INDIRUBIN-3'-OXIME DERIVATIVES AS POTENT CYCLIN DEPENDENT KINASE INHIBITORS - The present invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and/or human breast cancer cell. | 11-22-2012 |
20100056456 | Omega Conotoxins - The present invention relates to a method for increasing the binding reversibility of a ω-conotoxin to a N-type calcium channel, which comprises preparing a ω-conotoxin having a Ile and/or Ala residue at a position of amino acid (11 and/or 12), respectively in the second loop between cysteine residues (2 and 3) of the ω-conotoxin represented by the formula I, such that the prepared ω-conotoxin has the increased binding reversibility to N-type calcium channel. In addition, the present invention relates to a novel ω-conotoxin and a pharmaceutical composition having plausible properties in view of blocking activity to and specificity to N-type calcium channel, and dramatically improved binding reversibility to N-type calcium channel. | 03-04-2010 |
20090041673 | Thermally Crosslinked Contrast Agents - The present invention relates to a contrast agent comprising a plurality of nanoparticles, wherein each of the nanoparticles comprises: (a) a signal generating core; and (b) a polymeric shell coated on the signal generating core, wherein the polymeric shell comprises a water soluble hydoxysilyl- or alkoxysilyl-functionalized polymer and wherein the polymer shell is thermally crosslinked through hydroxysilyl or alkoxysilyl groups of the polymer. | 02-12-2009 |